Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer

被引：1
|
作者：
Hasenburg, A. [1 ]
van de Velde, C. J. H. [2 ]
Seynaeve, C. [3 ]
Rea, D. W. [4 ]
Vannetzel, J. [5 ]
Paridaens, R. [6 ]
Markopoulos, C. [7 ]
Hozumi, Y. [8 ]
Putter, H. [2 ]
Jones, S. E. [9 ]
机构：
[1] Univ Med Ctr, Freiburg, Germany
[2] Univ Med Ctr, Leiden, Netherlands
[3] Erasmus MC, Rotterdam, Netherlands
[4] Univ Birmingham, Birmingham, W Midlands, England
[5] Inst Sein Henri Hartmann, Neuilly Sur Seine, France
[6] Univ Hosp Gasthuisberg, Louvain, Belgium
[7] Univ Med Sch, Athens, Greece
[8] Jichi Med Univ, Shimotsuke, Japan
[9] US Oncol Res, Med Oncol, Houston, TX USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70047-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [1] Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.
    Rea, D.
    Hasenburg, A.
    Seynaeve, C.
    Jones, S. E.
    Vannetzel, J-M
    Paridaens, R.
    Markopoulos, C.
    Hozumi, Y.
    Putter, H.
    Hille, E.
    Asnar, L.
    Urbanski, R.
    van de Velde, C. H.
    Bartlett, J. M. S.
    Smeets, J.
    Kieback, D. G.
    CANCER RESEARCH, 2009, 69 (24) : 487S - 487S
  • [2] Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer
    van de Velde, C.
    Seynaeve, C.
    Hasenburg, A.
    Rea, D.
    Vannetzel, J. M.
    Paridaens, R.
    Markopoulos, C.
    Smeets, J.
    Nortier, J. W. R.
    Jones, S. E.
    EJC SUPPLEMENTS, 2009, 7 (03): : 1 - 1
  • [3] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
    Coombes, RC
    Hall, E
    Gibson, LJ
    Paridaens, R
    Jassem, J
    Delozier, T
    Jones, SE
    Alvarez, I
    Bertelli, G
    Ortmann, O
    Coates, AS
    Bajetta, E
    Dodwell, D
    Coleman, RE
    Fallowfield, LJ
    Mickiewicz, E
    Andersen, J
    Lonning, PE
    Cocconi, G
    Stewart, A
    Stuart, N
    Snowdon, CF
    Carpentieri, M
    Massimini, G
    Bliss, JM
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11): : 1081 - 1092
  • [4] Randomized, controlled phase II trial of exemestane compared with medroxyprogesterone after nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer
    Wang, T.
    Huang, H.
    Zhang, S.
    Bian, L.
    Jiang, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
    Barnadas, A.
    Gil, M.
    Gonzalez, S.
    Tusquets, I.
    Munoz, M.
    Arcusa, A.
    Prieto, L.
    Margeli-Vila, M.
    Moreno, A.
    BRITISH JOURNAL OF CANCER, 2009, 100 (03) : 442 - 449
  • [6] Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
    A Barnadas
    M Gil
    S González
    I Tusquets
    M Muñoz
    A Arcusa
    L Prieto
    M Margelí-Vila
    A Moreno
    British Journal of Cancer, 2009, 100 : 442 - 449
  • [7] Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
    Binghe Xu
    Huiping Li
    Zefei Jiang
    Lin Gu
    Jinhai Tang
    Hui Xie
    Yueyin Pan
    Yunjiang Liu
    Shude Cui
    Xiaojia Wang
    Li Cai
    Yiqiong Zhang
    Huadong Zhao
    Zhimin Shao
    Chinese Journal of Cancer Research, 2022, 34 (06) : 592 - 601
  • [8] Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
    Xu, Binghe
    Li, Huiping
    Jiang, Zefei
    Gu, Lin
    Tang, Jinhai
    Xie, Hui
    Pan, Yueyin
    Liu, Yunjiang
    Cui, Shude
    Wang, Xiaojia
    Cai, Li
    Zhang, Yiqiong
    Zhao, Huadong
    Shao, Zhimin
    CHINESE JOURNAL OF CANCER RESEARCH, 2022, 34 (06) : 592 - +
  • [9] Quality of life in the intergroup exemestane study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer
    Fallowfield, LJ
    Bliss, JM
    Porter, LS
    Price, MH
    Snowdon, CF
    Jones, SE
    Coombes, RC
    Hall, E
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 910 - 917
  • [10] Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase Ill trial in hormone sensitive postmenopausal early breast cancer
    Jones, S. E.
    Seynaeve, C.
    Hasenburg, A.
    Rae, D.
    Vannetzel, J-M
    Paridaens, R.
    Markopoulos, C.
    Hozumi, Y.
    Putter, H.
    Hille, E.
    Kieback, D.
    Asmar, L.
    Smeets, J.
    Urbanski, R.
    Bartlett, J. M. S.
    van de Velde, C. J. H.
    CANCER RESEARCH, 2009, 69 (02) : 67S - 67S
12345